Advances in implantable cardioverter defibrillator therapy. (3rd March 2016)

• Record Type: Journal Article
• Authors: Rickard, John; Wilkoff, Bruce L.
• Is Part Of: Expert review of cardiovascular therapy. Volume 14:Number 3(2016)
• Page Start: 291
• Page End: 299
• Publication Date: 2016-03-03
• Subjects: ICD -- ATP -- subcutaneous ICD -- MRI and ICD -- ICD programming; Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1586/14779072.2016.1131124
• Languages: English
• ISSNs: 1477-9072

Abstract

ABSTRACT: Since the first implant in 1980, implantable cardioverter defibrillator (ICD) technology has progressed rapidly. Modern ICD's have hundreds of programmable options with the general goal of preventing inappropriate shocks and providing shocks for truly life threatening symptomatic ventricular arrhythmias. New studies on ICD programming have shown the benefits of prolonged detection intervals in reaching this goal. Anti-tachycardia pacing (ATP) therapy has become an important adjunct to defibrillator shocks. Remote monitoring technologies have surfaced which have been shown to identify arrhythmias and problems with the device in an expedient fashion. The subcutaneous ICD offers the advantage of avoiding intravascular leads and their inherent risks. Lastly, the current understanding of the effects of MRI in ICD patients has advanced creating new opportunities to provide MRI safely to such patients.